Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease
Parkinson's disease (PD) is a chronic debilitating disease affecting approximately 1% of the population over the age of 60. The severity of PD is correlated to the degree of dopaminergic neuronal loss. Apomorphine has a similar chemical structure as the neurotransmitter dopamine and has been us...
Main Authors: | Nrupa Borkar, Huiling Mu, René Holm |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-11-01
|
Series: | Asian Journal of Pharmaceutical Sciences |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1818087617306189 |
Similar Items
-
Apomorphine in the treatment of Parkinson's disease: a review
by: Renata Ramina Pessoa, et al. -
Lipid nanoparticles as drug delivery systems for apomorphine
by: Hui Wen Chang, et al.
Published: (2010) -
Apomorphine in Parkinson's disease—The questions raised
by: Rajinder K Dhamija, et al.
Published: (2020-01-01) -
Pharmacokinetic and pharmcodynamic studies of apomorphine in the treatment of idiopathic Parkinson's disease
by: Ingram, Wendy Merewyn
Published: (2001) -
Continuous subcutaneous apomorphine monotherapy in Parkinson’s disease
by: Ewa Papuć, et al.
Published: (2019-03-01)